Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoreline versus Zoladex LA pharmacokinetic study in men with prostate cancer
2015-001756-30Phase 2Completed
- Sponsor
- Novalon S.A.
- Start
- Dec 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of goserelin in prostate cancer (PCa) (2 arms), sponsored by Novalon S.A. Primary endpoint: Maximum measured goserelin plasma concentration. Started Dec 2015; status: completed.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2015-001756-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001756-30.